title: Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease.
abstract: Alzheimer's disease (AD) is one of the most important neurodegenerative disorders, bringing about huge medical and social burden in the elderly worldwide. Many aspects of its pathogenesis have remained unclear and no effective treatment exists for it. Within the past 20 years, various mice models harboring AD-related human mutations have been produced. These models imitate diverse AD-related pathologies and have been used for basic and therapeutic investigations in AD. In this regard, there are a wide variety of preclinical trials of potential therapeutic modalities using AD mice models which are of paramount importance for future clinical trials and applications. This review summarizes more than 140 substances and treatment modalities being used in transgenic AD mice models from 2001 to 2011. We also discuss advantages and disadvantages of each model to be used in therapeutic development for AD.
authors.affiliation: Division of Immunopathology of the Nervous System, Department of Neuropathology, Institute of Pathology and Neuropathology, University of Tuebingen, Germany. lichaoyunseu@163.com
authors.forename: Chaoyun
authors.initials: C
authors.lastname: Li
authors.forename: Azadeh
authors.initials: A
authors.lastname: Ebrahimi
authors.forename: Hermann
authors.initials: H
authors.lastname: Schluesener
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004195:Disease Models, Animal; D055808:Drug Discovery; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics* / Q000502:physiology*; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000235:genetics*; D018697:Nootropic Agents / Q000627:therapeutic use*; D053763:Presenilins / Q000235:genetics; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D016875:tau Proteins / Q000235:genetics
chemical_list: D016564:Amyloid beta-Protein Precursor; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D053763:Presenilins; D016194:Receptors, N-Methyl-D-Aspartate; D016875:tau Proteins; D053829:Amyloid Precursor Protein Secretases